10-Q quarterly report · filed Nov 12, 2026

Eledon Pharmaceuticals, Inc. (ELDN) Q3 2026 10-Q Quarterly Report

Short answer

Eledon Pharmaceuticals, Inc. (ELDN) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$4M
+77.5% YoY · +87.6% QoQ
EPS (diluted)
−$0.04
+81.0% YoY · +84.6% QoQ

Source: XBRL data from the Eledon Pharmaceuticals, Inc. (ELDN) Q3 2026 10-Q on SEC EDGAR. USD.

Eledon Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no approved products or product sales
  • Operating margin not meaningful, operating loss $21.7M vs $19.1M YoY
  • R&D expenses $17.8M, up $2.8M YoY, driven by $5.1M higher manufacturing costs
  • Cash, equivalents and short-term investments $69.7M, operating cash use $64.3M for nine months
  • Phase 3 LEGACY planned for late 2026, additional financing required, substantial doubt about going concern

Risk Factors

  • Newly disclosed going-concern risk: $69.7 million liquidity does not fund operations for at least twelve months
  • Clinical-development risk: Phase 3 kidney-transplant trial and islet-cell program require substantial additional financing
  • Regulatory risk: 2025 Trump executive orders may alter FDA rules and delay approvals
  • Manufacturing risk: no redundant supply arrangements for custom drug-production materials
  • Competitive risk: Vertex and other larger companies developing immune-evasive islet-cell therapies

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Eledon Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.